European drugmakers Sanofi and GSK strike $2.1 billion deal with U.S. for a coronavirus vaccine
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Tech giants including Google and Amazon pledged support for a $5 million competition to accelerate cheap and fast COVID-19 testing in the U.S.
Submitted by mike kraft on
Submitted by mike kraft on
Billions of dollars are being invested in the development of vaccines against the coronavirus. Until one arrives, many scientists have turned to tried-and-true vaccines to see whether they may confer broad protection, and may reduce the risk of coronavirus infection, as well.
Old standbys like the Bacille Calmette-Guerin tuberculosis vaccine and the polio vaccine appear to help train the immune system to respond to a broad variety of infections, including from bacteria, viruses and parasites, experts say.
Submitted by mike kraft on
By Dr. Gavin Macgregor-Skinner | July 29, 2020
As an epidemiologist or “disease detective,” a question I am frequently asked regarding SARS-CoV-2 (the virus that causes COVID-19 disease) is: “How does someone become infected?”
Submitted by mike kraft on
Submitted by mike kraft on
Costa Rica is set to begin clinical trials on antibody-rich plasma that has been extracted from horses with the purpose of treating COVID-19 patients.
Two versions of the plasma were shown to inhibit the infectivity of SARS-CoV-2, the virus that causes COVID-19, in tests performed at the National Center for Biodefense and Infectious Diseases in the United States.
Submitted by mike kraft on
In a laboratory in New York City, researchers coaxed a key piece of the coronavirus — its infamous outer “spike” — to mutate so that it became invisible to disease-fighting antibodies, according to a new study that has not yet been published in a scientific journal.
Submitted by mike kraft on
Submitted by mike kraft on